Amunix, Inc. Announces Licensing Agreement for Its Proprietary XTEN Technology
Published: Jan 22, 2013
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Amunix, Inc., today announced that it has entered into a worldwide research collaboration and licensing agreement with Janssen Biotech, Inc. and its affiliates (“Janssen”). Amunix will combine its XTEN half-life extension technology with protein and/or peptide therapeutics selected by Janssen. Under the terms of the agreement, Amunix will assist Janssen in the engineering of up to three XTEN fusion proteins. Janssen will be responsible for all preclinical and clinical development as well as for manufacturing and commercialization of the resulting products. Amunix will receive an initial upfront payment in addition to R&D funding and will be eligible for future milestone and royalty payments. Additional financial terms will not be disclosed.